Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201472 | 1.00 | TDP1 (0.41) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL3836310 | 1.00 | TDP1 (0.41) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL6154152 | 0.88 | TDP1 (0.46) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL1907257 | 0.82 | TDP1 (0.42) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL2201739 | 0.81 | TDP1 (0.41) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL6530600 | 0.81 | TSHR (0.49) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL9749118 | 0.81 | TSHR (0.49) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL2201733 | 0.81 | TDP1 (0.41) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL6532603 | 0.81 | TDP1 (0.41) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 | |
| SCHEMBL7577258 | 0.81 | TDP1 (0.41) | TDP1TSHRCYP3A4NPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937696-B1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS (SI) | 2013-05-22 | — | — | EP | claimed |
| US-8269001-B2 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2012-09-18 | — | — | US | claimed |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-04 | — | — | US | claimed |
| EP-1937696-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK Pharmaceuticals D.D. (SI) | 2008-07-02 | — | — | EP | claimed |
| WO-2007139238-A1 | PROCESS FOR L-CARNITINE AND ACETYL L-CARNITINE HYDROCHLORIDE | ENZYTECH, LTD. (KR) | 2007-12-06 | — | — | WO | claimed |
| EP-1775299-A1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK Pharmaceuticals D.D. (SI) | 2007-04-18 | — | — | EP | claimed |
| WO-2007039287-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2007-04-12 | — | — | WO | claimed |
| US-9758471-B2 | Process for the preparation of 4-dimethylaminocrotonic acid | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20170107172-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-04-20 | — | — | US | disclosed |
| EP-3148977-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | Sun Pharmaceutical Industries Ltd (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186065-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
| US-8779192-B2 | Process of preparing an alkylamine derivative | KOLON LIFE SCIENCE, INC. | 2014-07-15 | — | — | US | disclosed |
| EP-2341054-B1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS (SI) | 2014-06-25 | — | — | EP | disclosed |
| EP-0223328-B1 | PROCESS FOR PRODUCING OXIRACETAM | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-01-29 | — | — | EP | disclosed |
| US-4940823-A | Process for optically active 3-thiolanyl sulfonate esters | PFIZER INC. (US) | 1990-07-10 | — | — | US | disclosed |
| US-4921972-A | Process for optically active 3-thiolanyl sulfonate esters | PFIZER INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-4895979-A | HYDROGENATION OF GAMMA-HALO-BETA-KETO ESTER, RUTHENIUM-OPTICALLY ACTIVE PHOSPHINE CATALYST, QUATERNIZATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0339764-A1 | Process for preparing carnitine | Takasago International Corporation (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4686296-A | Process for producing oxiracetam | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-08-11 | — | — | US | disclosed |
| EP-0223328-A1 | Process for producing oxiracetam | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107172-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | EGFR, MET, ABL1 | TDP1 4260/4885TSHR 730/4885CYP3A4 50/4885 |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | HMGCR, COASY, LSS | TDP1 3797/4885TSHR 4186/4885CYP3A4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.